Digital supply chain pilot backed by UK government

18 August 2021

In the UK, a consortium of public and private companies have been awarded part of a £53 million ($73 million) grant from UK Research and Innovation (UKRI) and the Made Smarter initiative.

Industry partners Catalent (NYSE: CTLT), Siemens, GlaxoSmithKline (LSE: GSK) and AstraZeneca (LSE: AZN) are among the companies which will work together to introduce a proof of concept approach to a new digital supply chain.

The Digital Medicines Manufacturing Research Centre will be based at Strathclyde, Cambridge and Loughborough Universities, and will aim to create digital supply chains enabling clinical trials to operate more flexibly.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK